The company has dedicated manufacturing in Harmans, MD under a strategic partnership agreement with Paragon Gene Therapy. This cGMP suite will support future clinical and commercial production for Passage therapies and is expected to be operational in the second half of 2020. We have selected iCELLis, a superior manufacturing platform, for the development of our products. This fully-integrated bioreactor system can handle clinical and commercial-scale volumes and provides excellent cell growth conditions for adherent cells.